glp-1 news 2025 november 25 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 The GLP-1 Access Gap: Mapping
Description
We need to have a more balanced conversation about GLP-1 medications
Australia's medicines regulator issues a safety warning over the potential risk of suicidal thoughts and behaviours when taking Ozempic-style drugs.
Glenn Lyle in Raleigh, NC.
A study assessed the kidney benefits of metabolic surgery compared to glucagon-like peptide-1 receptor agonist treatment in patients with obesity and chronic kidney disease (CKD).
Overindulging in rich foods while taking a drug like Wegovy or Zepbound can raise the risk of side effects like nausea and bloating
